Beyond its motor features, Huntington's disease commonly presents with neuropsychiatric symptoms that significantly affect daily functioning. Apathy is one of the most clinically important of these, yet it can be challenging to recognise and address in practice.
Apathy in Huntington's disease has been characterised as a quantifiable reduction in goal-directed behavior, manifesting clinically as decreased interest, spontaneity, motivation, and drive. It represents a distinct neuropsychiatric feature requiring targeted, structured management.
Management involves a combination of structured, activity-based non-pharmacological strategies and careful pharmacological review. Specific interventions are personalised to the individual. Both the patient's activity patterns and their existing medication profile are relevant considerations. The complete regimen — including sequencing, pharmacological options, and clinical decision points — is available in the full protocol.
Apathy has been defined by Levy and Czernecki (84) as "a quantifiable reduction in goal-directed behavior," manifesting clinically as a reduction in interest, spontaneity, motivation, and drive.
Personalized cognitive stimulation, establishing routines and a structured programme of activities is recommended when possible.
Depression may increase apathy. If depression is suspected, an SSRI should be tried.
Sedative medication may increase apathy, thus avoiding unnecessary prescription or reduce dosage is recommended.
View source ↗